Avalo Therapeutics (NASDAQ:AVTX) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Thursday,RTT News reports. Wedbush currently has a $18.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the stock. Piper Sandler initiated coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 price objective for the company. BTIG Research initiated coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.33.

Avalo Therapeutics Price Performance

NASDAQ:AVTX opened at $8.22 on Thursday. Avalo Therapeutics has a fifty-two week low of $4.43 and a fifty-two week high of $34.46. The company has a 50 day simple moving average of $7.44 and a two-hundred day simple moving average of $9.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its holdings in shares of Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after purchasing an additional 3,754 shares during the period. Marshall Wace LLP bought a new stake in Avalo Therapeutics in the 4th quarter valued at about $114,000. Walleye Capital LLC acquired a new position in Avalo Therapeutics during the 4th quarter worth approximately $145,000. Northern Trust Corp bought a new position in Avalo Therapeutics in the fourth quarter worth approximately $168,000. Finally, Bank of Montreal Can acquired a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $446,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.